PapersPMID:38542695
The Effects of Cranberry Consumption on Glycemic and Lipid Profiles in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- findings
- 7
- compound
- 1
- endpoints
- 7
- no difference found
- 6
- Study, every finding
- meta-analysis
- Dose studied, every finding
- Pooled doses: capsules or tablets 144 to 1500 mg/day, powder 9 g/day, juice 240 to 750 mL/day; intervention length 2 weeks to 6 months
What moved
How to read these marks →- Decreases HOMA-IR
moderate
“In terms of glycemic indicators, HOMA-IR was investigated in five studies, and the pooled estimates suggested that cranberry significantly reduced HOMA-IR (MD = −0.59; 95% CI: −1.05, −0.14; peffect = 0.01; Figure 4D), whereas cranberry supplementation did not show significant alterations to FBG (MD = −0.09; 95% CI: −0.23, 0.04; peffect = 0.17), HbA1c (MD = −0.16; 95% CI: −0.38, 0.05; peffect = 0.13), and fasting insulin (MD = −1.31; 95% CI: −2.85, 0.22; peffect = 0.09).”
- Effect
- −0.59 mean difference, 95% CI −1.05 to −0.14
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate from five studies
What did not
- Effect
- −0.09 mean difference, 95% CI −0.23 to 0.04
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
- Effect
- −0.16 mean difference, 95% CI −0.38 to 0.05
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
“However, no significant decrease or increase was observed between cranberry supplementation and other blood lipid profiles: TC (MD = −0.11; 95% CI: −0.26, 0.03; peffect = 0.12), HDL-C (MD = −0.02; 95% CI: −0.05, 0.01; peffect = 0.25), LDL-C (MD = −0.10; 95% CI: −0.20, 0.01; peffect = 0.07), and TG (MD = 0.06; 95% CI: 0.00, 0.12; peffect = 0.05).”
- Effect
- −0.11 mean difference, 95% CI −0.26 to 0.03
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
- Effect
- −0.02 mean difference, 95% CI −0.05 to 0.01
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
- Effect
- −0.1 mean difference, 95% CI −0.2 to 0.01
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
- Effect
- 0.06 mean difference, 95% CI 0 to 0.12
- Population
- Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
Study record
- Design
- meta-analysis
- Species
- human
- Population
- adults aged 18 to 80 in 16 randomized controlled trials of cranberry supplementation (healthy, overweight or obesity, diabetes, CVD, metabolic syndrome, NAFLD)
- Participants
- 708
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 10